Clinical Trial for the Prevention of Vasovagal Syncope

PHASE4CompletedINTERVENTIONAL
Enrollment

213

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Syncope, Vasovagal, Neurally-Mediated
Interventions
DRUG

fludrocortisone acetate

Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily

Trial Locations (14)

02118

Boston University, Boston

37232-2195

Vanderbilt University, Nashville

23225-3838

Virginia Cardiovascular Specialists, Richmond

T2N 4N1

University of Calgary, Faculty of Medicine, Calgary

T3B 6A8

Alberta Children's Hospital, Calgary

R2H 2A6

St. Boniface General Hospital, Winnipeg

B3H 3A7

Queen Elizabeth II, Halifax Infirmary, Halifax

L8L 2X2

McMaster University, Hamilton Health Sciences, Hamilton

K7V 2V7

Queen's University, Kingston

N6A 5A5

University of Western Ontario, London Health Sciences, London

K1Y 4W7

University of Ottawa, Ottawa Heart Institute, Ottawa

M5B 1W8

St. Michael's Hospital, Toronto

H1T 1C8

Institut de Cardiologie de Montreal, Montreal

H4J 1C5

Hopital Sacre Coeur de Montreal, Montreal

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of Calgary

OTHER

NCT00118482 - Clinical Trial for the Prevention of Vasovagal Syncope | Biotech Hunter | Biotech Hunter